PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 135 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $186,516 | -37.2% | 11,182 | +4.0% | 0.00% | 0.0% |
| Q2 2023 | $297,052 | +45.3% | 10,755 | +21.0% | 0.00% | 0.0% |
| Q1 2023 | $204,378 | -35.5% | 8,886 | -33.7% | 0.00% | 0.0% |
| Q1 2022 | $317,000 | -43.8% | 13,399 | -18.7% | 0.00% | 0.0% |
| Q4 2021 | $564,000 | +100.0% | 16,489 | +3.8% | 0.00% | 0.0% |
| Q3 2021 | $282,000 | -66.3% | 15,892 | -14.7% | 0.00% | -50.0% |
| Q2 2021 | $836,000 | +110.1% | 18,621 | +21.2% | 0.00% | +100.0% |
| Q1 2021 | $398,000 | +53.1% | 15,367 | +19.4% | 0.00% | 0.0% |
| Q4 2020 | $260,000 | – | 12,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |